伏立康唑群体药动学研究及其在给药方案设计中的应用进展
|
摘要
伏立康唑作为侵袭性真菌感染的一线治疗药物,广泛应用于临床,但该药物治疗窗窄,药物的药动学性质具有较大的个体间及个体内变异。本文通过检索有关伏立康唑群体药动学研究的国内外文献,对其进行汇总分析。阐述伏立康唑在侵袭性真菌感染患者、移植患者和免疫缺陷患者中的群体药动学特征,及其在给药方案设计中的应用,进而为提高伏立康唑治疗有效率,减少不良反应发生,推进临床个体化给药提供理论依据。
Voriconazole is widely used as the first-line treatment for invasive fungal infections,but its therapeutic window is narrow,and inter-individual and intra-individual variability in voriconazole pharmacokinetic properties is high. Here,we analyzed the domestic and foreign literatures on the population pharmacokinetics of voriconazole and summarized the population pharmacokinetic characteristics of voriconazole in patients with invasive fungal infections,transplant patients or immunodeficiency patients,and the application in the design of dosage regimen,to improve drug treatment efficiency,reduce the occurrence of adverse reactions,thereby providing theoretical basis for clinically individualized voriconazole administration.
Voriconazole is widely used as the first-line treatment for invasive fungal infections,but its therapeutic window is narrow,and inter-individual and intra-individual variability in voriconazole pharmacokinetic properties is high. Here,we analyzed the domestic and foreign literatures on the population pharmacokinetics of voriconazole and summarized the population pharmacokinetic characteristics of voriconazole in patients with invasive fungal infections,transplant patients or immunodeficiency patients,and the application in the design of dosage regimen,to improve drug treatment efficiency,reduce the occurrence of adverse reactions,thereby providing theoretical basis for clinically individualized voriconazole administration.
引文
[1]孙浩,杜晓明,庞露,等.伏立康唑在不同人群个体化给药方案研究现状[J].中国感染与化疗杂志,2016,16(1):99-103.
[2]陈恳,李光耀,翟所迪.伏立康唑治疗药物监测有效性和安全性的系统评价[J].中国临床药理学杂志,2017,33(1):80-83.
[3]陈恳,李晓菲,唐惠林,等.不同细胞色素P4502C19基因型患者伏立康唑稳态血药谷浓度的系统评价[J].中国临床药理学杂志,2016,32(3):264-266.
[4]何子剑,詹莹,邵华,等.基于最大后验贝叶斯法的临床药动学采样点优化研究的文献分析[J].中国药房,2018,29(2):210-215.
[5]李紫薇,颜苗,彭风华,等.伏立康唑在肾移植患者中的群体药动学研究[J].中国医院药学杂志,2017,37(3):221-226.
[6]汪洋,梅艳,李思婵,等.应用蒙特卡洛模拟探索不同CYP2C19基因型侵袭性真菌感染患者的伏立康唑最佳用药方案[J].中国医院药学杂志,2018,38(1):1-4.
[7]牛丙寅,王冠,陈世才,等.CYP2C19基因多态性检测指导下的伏立康唑治疗侵袭性真菌感染患者效果的评价[J].首都医科大学学报,2018,39(3):423-427.
[8]张弨.伏立康唑的药效学研究评价[J].中国临床药理学与治疗学,2018,23(1):116-120.
[9]Han K,Capitano B,Bies R,et al.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients[J].Antimicrob Agents Chemother,2010,54(10):4424-4431.
[10]Han K,Bies R,Johnson H,et al.Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients[J].Clin Pharmacokine,2011,50(3):201-214.
[11]Liu P,Mould DR.Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis[J].Antimicrob Agents Chemother,2014,58(8):4718-4726.
[12]Muto C,Shoji S,Tomono Y,et al.Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects[J].Antimicro Agents Chemother,2015,59(6):3216-3223.
[13]Pascual A,Csajka C,Buclin T,et al.Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety:population pharmacokinetics-based analysis of adult patients with invasive fungal infections[J].Clin Infect Dis,2012,55(3):381-390.
[14]Wang T,Chen S,Sun J,et al.Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections[J].J Antimicrob Chemother,2014,69(2):463-470.
[15]Ashbee HR,Barnes RA,Johnson EM,et al.Therapeutic drug monitoring(TDM)of antifungal agents:guidelines from the British Society for Medical Mycology[J].J Antimicrob Chemother,2014,69(5):1162-1176.
[16]李静静,刘艺茜,唐莲,等.新生儿万古霉素的群体药动学研究[J].中国药学杂志,2017,52(16):1434-1441.
[17]Samara E,Granneman R.Role of population pharmacokinetics in drug development.A pharmaceutical industry perspective[J].Clin Pharmacokine,1997,32(4):294-312.
[18]Dolton MJ,Mikus G,Weiss J,et al.Understanding variability with voriconazole using a population pharmacokinetic approach:implications for optimal dosing[J].JAntimicrob Chemother,2014,69(6):1633-1641.
[19]Friberg E,Ravva P,Karlsson MO,et al.Integrated population pharmacokinetic analysis of voriconazole in children,adolescents,and adults[J].Antimicrob A-gents Chemother,2012,56(6):3032-3042.
[20]Klotz U.Pharmacokinetics and drug metabolism in the elderly[J].Drug Metab Rev,2009,41(2):67-76.
[21]Luong ML,AI-Dabbagh M,Groll AH,et al.Utility of voriconazole therapeutic drug monitoring:a meta-analysis[J].J Antimicrob Chemother,2016,71(7):1786-1799.
[22]Matsumoto K,Abematsu K,Shigemi A,et al.Therapeutic drug monitoring of voriconazole in Japanese patients:analysis based on clinical practice data[J].JChemother,2016,28(3):198-202.
[23]Lin SJ,Schranz J,Teutsch SM.Aspergillosis case-fatality rate:systematic review of the literature[J].Clin Infect Dis,2001,32(3):358-366.
[24]Zheyu C,Lunan Y.Early changes of small intestine function in rats after liver transplantation[J].Transplant Proc,2006,38(5):1564-1568.
[25]曹存巍,罗宏,郑艳青,等.获得性免疫与真菌感染的相关性[J].皮肤科学通报,2017,34(5):531-539.
[26]Boast A,Curtis N,Cranswick N,et al.Voriconazole dosing and therapeutic drug monitoring in children:experience from a pediatric tertiary care center[J].JAntimicrob Chemother,2016,71(7):2031-2036.
[2]陈恳,李光耀,翟所迪.伏立康唑治疗药物监测有效性和安全性的系统评价[J].中国临床药理学杂志,2017,33(1):80-83.
[3]陈恳,李晓菲,唐惠林,等.不同细胞色素P4502C19基因型患者伏立康唑稳态血药谷浓度的系统评价[J].中国临床药理学杂志,2016,32(3):264-266.
[4]何子剑,詹莹,邵华,等.基于最大后验贝叶斯法的临床药动学采样点优化研究的文献分析[J].中国药房,2018,29(2):210-215.
[5]李紫薇,颜苗,彭风华,等.伏立康唑在肾移植患者中的群体药动学研究[J].中国医院药学杂志,2017,37(3):221-226.
[6]汪洋,梅艳,李思婵,等.应用蒙特卡洛模拟探索不同CYP2C19基因型侵袭性真菌感染患者的伏立康唑最佳用药方案[J].中国医院药学杂志,2018,38(1):1-4.
[7]牛丙寅,王冠,陈世才,等.CYP2C19基因多态性检测指导下的伏立康唑治疗侵袭性真菌感染患者效果的评价[J].首都医科大学学报,2018,39(3):423-427.
[8]张弨.伏立康唑的药效学研究评价[J].中国临床药理学与治疗学,2018,23(1):116-120.
[9]Han K,Capitano B,Bies R,et al.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients[J].Antimicrob Agents Chemother,2010,54(10):4424-4431.
[10]Han K,Bies R,Johnson H,et al.Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients[J].Clin Pharmacokine,2011,50(3):201-214.
[11]Liu P,Mould DR.Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis[J].Antimicrob Agents Chemother,2014,58(8):4718-4726.
[12]Muto C,Shoji S,Tomono Y,et al.Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects[J].Antimicro Agents Chemother,2015,59(6):3216-3223.
[13]Pascual A,Csajka C,Buclin T,et al.Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety:population pharmacokinetics-based analysis of adult patients with invasive fungal infections[J].Clin Infect Dis,2012,55(3):381-390.
[14]Wang T,Chen S,Sun J,et al.Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections[J].J Antimicrob Chemother,2014,69(2):463-470.
[15]Ashbee HR,Barnes RA,Johnson EM,et al.Therapeutic drug monitoring(TDM)of antifungal agents:guidelines from the British Society for Medical Mycology[J].J Antimicrob Chemother,2014,69(5):1162-1176.
[16]李静静,刘艺茜,唐莲,等.新生儿万古霉素的群体药动学研究[J].中国药学杂志,2017,52(16):1434-1441.
[17]Samara E,Granneman R.Role of population pharmacokinetics in drug development.A pharmaceutical industry perspective[J].Clin Pharmacokine,1997,32(4):294-312.
[18]Dolton MJ,Mikus G,Weiss J,et al.Understanding variability with voriconazole using a population pharmacokinetic approach:implications for optimal dosing[J].JAntimicrob Chemother,2014,69(6):1633-1641.
[19]Friberg E,Ravva P,Karlsson MO,et al.Integrated population pharmacokinetic analysis of voriconazole in children,adolescents,and adults[J].Antimicrob A-gents Chemother,2012,56(6):3032-3042.
[20]Klotz U.Pharmacokinetics and drug metabolism in the elderly[J].Drug Metab Rev,2009,41(2):67-76.
[21]Luong ML,AI-Dabbagh M,Groll AH,et al.Utility of voriconazole therapeutic drug monitoring:a meta-analysis[J].J Antimicrob Chemother,2016,71(7):1786-1799.
[22]Matsumoto K,Abematsu K,Shigemi A,et al.Therapeutic drug monitoring of voriconazole in Japanese patients:analysis based on clinical practice data[J].JChemother,2016,28(3):198-202.
[23]Lin SJ,Schranz J,Teutsch SM.Aspergillosis case-fatality rate:systematic review of the literature[J].Clin Infect Dis,2001,32(3):358-366.
[24]Zheyu C,Lunan Y.Early changes of small intestine function in rats after liver transplantation[J].Transplant Proc,2006,38(5):1564-1568.
[25]曹存巍,罗宏,郑艳青,等.获得性免疫与真菌感染的相关性[J].皮肤科学通报,2017,34(5):531-539.
[26]Boast A,Curtis N,Cranswick N,et al.Voriconazole dosing and therapeutic drug monitoring in children:experience from a pediatric tertiary care center[J].JAntimicrob Chemother,2016,71(7):2031-2036.